Hematology and Oncology Book

//fpnotebook.com/

Polycythemia Rubra Vera

Aka: Polycythemia Rubra Vera, Polycythemia Vera
  1. Definitions
    1. Polycythemia Rubra Vera
      1. Excessive Red Blood Cell production due to chronic myeloproliferative neoplasm
  2. Epidemiology
    1. Men affected more than women
    2. Age
      1. Median age of onset: 60-64 years old
      2. Under age 40 years old represent 20-25% of cases
    3. Incidence: 2.3 per 100,000 persons per year
    4. Prevelance: 44-57 per 100,000 persons (U.S.)
  3. Pathophysiology
    1. Chronic myeloproliferative neoplasm (primary Polycythemia Vera)
      1. Other common myeloproliferative disorders include Essential Thrombocythemia and Myelofibrosis
      2. Associated with Janus Kinase 2 gene (JAK2) resulting in unregulated hematopoiesis
        1. JAK2 V617F mutation (96% of polycythemia cases)
        2. JAK2 exon 12 mutations (3% of polycythemia patients)
      3. Primarily causes erythrocytosis
      4. Also causes Leukocytosis and Thrombocytosis
    2. Excessive Red Blood Cell production (erythrocytosis)
      1. Results in increased blood viscosity and Blood Volume
      2. Ultimately results in thrombosis
  4. Risk Factors
    1. Non-modifiable
      1. Older age
      2. Male gender
      3. Caucasian
      4. European descent
    2. Modifiable
      1. Tobacco Abuse
      2. Obesity
      3. Hypertension
      4. Hyperlipidemia
      5. Diabetes Mellitus
  5. Differential Diagnosis
    1. Primary Polycythemia or Erythrocytosis
      1. Polycythemia Rubra Vera
      2. 2,3 Bisphosphoglycerate Deficiency (2,3 BPG Deficiency)
      3. Lindau-Von Hippel Disease
      4. Primary Familial and Congenital Polycythemia (EPOR)
      5. Other myeloproliferative neoplasm
        1. Essential Thrombocytosis or Thrombocythemia
        2. Primary Myelofibrosis
        3. Chronic Myelogenous Leukemia
        4. Myelodysplastic Syndrome
    2. Secondary Polycythemia or Erythrocytosis
      1. Decreased plasma volume or hemoconcentration (e.g.. Dehydration)
      2. Living at high altitude
        1. See High Altitude Related-Conditions
      3. Chronic heart or lung disease
        1. Chronic Hypoxia
        2. Left to Right Shunt
        3. Obesity hypoventilation syndrome
        4. Pickwickian Syndrome
        5. Sleep Apnea
      4. Drug-Induced or Toxin-Induced Polycythemia
        1. Tobacco Abuse (Smoker's Polycythemia)
        2. Anabolic Steroids
        3. Testosterone Replacement
        4. Erythropoietin
        5. Blood Doping
        6. Methemoglobinemia
        7. Chronic Carbon Monoxide Poisoning
      5. Renal Disease
        1. Renal Artery Stenosis
        2. Hydronephrosis
        3. Renal Transplant
      6. Erythropoietin secreting tumor
        1. Hepatocellular Carcinoma
        2. Renal Cell Carcinoma
        3. Hemangioblastoma
        4. Pheochromocytoma
        5. Uterine Leiomyomata
  6. Symptoms
    1. Thrombotic event on presentation: 20-39% of cases
      1. Cerebrovascular Accident (CVA) or Transient Ischemic Attack (TIA)
      2. Myocardial Infarction
      3. Peripheral arterial thrombosis
      4. Deep Vein Thrombosis
      5. Portal Vein Thrombosis or hepatic vein thrombosis (budd-chiari syndrome)
    2. Constitutional symptoms
      1. Fatigue (88%)
      2. Weight loss (31%)
      3. Night Sweats (52%)
      4. Insomnia
      5. Difficult Concentration
      6. Weakness
      7. Fever (18%)
    3. Generalized symptoms
      1. Pruritus (62%)
        1. Generalized burning, itching or Paresthesias
        2. Onset often within 10 minutes and lasting for up to 40 minutes after provocative exposure
        3. Provoked by bathing, especially in warm water (Aquagenic Pruritus)
        4. Also provoked by Temperature changes, Alcohol, Exercise
      2. Bone pain (50%)
      3. Gout history
    4. Microvascular Occlusion symptoms
      1. Headache
      2. Tinnitus
      3. Dizziness
      4. Visual disturbance
      5. Transient Ischemic Attack symptoms
      6. Distal Paresthesias
      7. Acrocyanosis
      8. Erythromelalgia (29% of cases)
        1. Vasomotor findings with extremity congestion, redness, burning pain
        2. Improves with Aspirin
    5. Splenomegaly related symptoms
      1. Abdominal Pain
      2. Early satiety
      3. Weight loss
      4. Nausea
  7. Signs
    1. See complications below
    2. Splenomegaly (35-45% of patients, especially in advanced Polycythemia Vera)
    3. Plethoric facies
      1. Ruddy facial Cyanosis
    4. Eyes
      1. Retinal vein engorgement
      2. Conjunctival small vessel injection
  8. Labs
    1. Red Blood Cell related increases
      1. Elevated Hemoglobin And Hematocrit (often found incidentally)
        1. White men: Hemoglobin >18.5 mg/dl (Hematocrit >52%)
        2. Black men: Hemoglobin >16 mg/dl (Hematocrit >47%)
        3. Women: >16.5 mg/dl (Hematocrit >48%)
      2. Elevated Red Blood Bell count
        1. RBC Count >36 ml/kg in men (>33 ml/kg in women)
    2. Proliferation of other cell lines (50% of patients)
      1. Platelet Count (median): 400k/mm3
      2. Leukocyte count (median) 10.4k/mm3
    3. Liver Function Tests
      1. LDH increased in 50% of patients
    4. Diagnostic Testing (indicated for diagnosis after erythrocytosis found)
      1. Janus Kinase 2 Mutation (JAK2 V617F mutation
      2. Erythropoetin Level
      3. Bone Marrow Biopsy
        1. Fluorescence in situ hybridization
        2. Karyotype
  9. Diagnosis: 2016 Revised WHO Criteria
    1. Major Criteria (both required)
      1. Increased red cell mass (erythrocytosis)
        1. Precaution: May miss masked Polycythemia Vera who are JAK2+, but normal RBC mass
        2. Men
          1. Hemoglobin >18.5 g/dl (WHO) or
          2. Hematocrit >52% (BCSH PVSG) or
          3. RBC Count >25% mean normal per WHO (e.g. >36 ml/kg)
        3. Women
          1. Hemoglobin >16.5 g/dl (WHO) or
          2. Hematocrit >48% (BCSH PVSG) or
          3. RBC Count >25% mean normal per WHO (e.g. >33 ml/kg)
      2. Bone Marrow Biopsy with hypercellularity for age
        1. Trilineage growth (erythroid, granulocytic, megakaryocytic) AND
        2. Pleomorphic mature Megakaryocytes
    2. Minor Criteria (at least one required)
      1. Janus Kinase 2 Mutation (JAK2 V617F mutation, JAK2 exon 12 mutation or similar)
        1. Present in 98% of patients with Polycthemia Vera
      2. Serum erythropoetin level below normal reference range
        1. Present in 81% of patients with Polycthemia Vera
        2. Test Sensitivity: 70%
        3. Test Specificity: 90%
    3. No obvious secondary polycythemia cause
      1. Normal arterial Oxygen Saturation (>92%)
    4. Interpretation
      1. Polycythemia Vera is unlikely if JAK2 V617F negative AND Erythropoietin normal or high
      2. All other JAK2 V617F and Erythropoietin results (with erythrocytosis) prompt Bone Marrow Biopsy
  10. Complications
    1. Accelerated atherosclerotic and thrombotic disease
      1. Cerebrovascular Accident
      2. Myocardial Infarction
      3. Peripheral Vascular Disease
      4. Other rarely affected vessels
        1. Mesenteric thrombosis
        2. Hepatic vein thrombosis or Portal Vein Thrombosis
    2. Hemorrhage and Bleeding Diathesis with extreme Thrombocytosis >1.5M (acquired Von Willebrand Syndrome)
      1. Epistaxis
      2. Acute GI Bleed
    3. Myeloproliferative Disease Progression (typically after 10 years of PCV)
      1. Myelofibrosis (20% of patients)
      2. Acute Myeloid Leukemia (5% of patients)
  11. Management: General
    1. Myelosuppression and other red cell reduction management is not currative
      1. Goals are to improve survival and improve quality of life, reduce symptoms and complications
      2. No treatment to date has been shown to reduce progression to Leukemia or Myelofibrosis
    2. Monitoring
      1. Repeat exam and labs (Complete Blood Count) every 3 to 6 months
    3. Risk Factor Reduction
      1. Tobacco Cessation
    4. Goal: Keep Hematocrit below threshold
      1. White men: Hematocrit <45%
      2. Black patients and all women: Hematocrit <42% (some guidelines recommend <45% in all patients)
      3. Phlebotomy reduces risk of thrombosis and improves survival
        1. Marchioli (2013) N Engl J Med 368(1): 22-33 [PubMed]
        2. Podoltsev (2018) Blood Adv 2(20): 2681-90 [PubMed]
    5. Low risk (age <60 years old without prior thrombosis)
      1. Repeated phlebotomy
      2. Low dose Aspirin (40 to 100 mg)
        1. Decreased risk of thrombotic events (MI, CVA, VTE) as well as decreased symptoms (e.g. Headache, Pruritus)
        2. Avoid in severe Thrombocytosis (>1000 x10^9) due to risk of acquired Von Willebrand Deficiency
        3. Landolfi (2004) N Engl J Med 350(2): 114-24 [PubMed]
    6. High risk (age >60 years old OR prior thrombosis, possibly Leukocytosis >10k/mm3)
      1. First-line
        1. Hydroxyurea
          1. Adverse effects include Anemia, Neutropenia, Oral Ulcers and Skin Ulcers, Hyperpigmentation
          2. Leukemogenicity risk (Exercise caution in age under 40 years old)
            1. Leukemic transformation 0.4% persons per year
            2. Myelofibrosis 5% at five years, 33.7% at 10 years
            3. Ferrari (2019) Hematologica 104(12): 2391-9 [PubMed]
      2. Anticoagulation and antiplatelet agent indications
        1. Arterial Thrombosis history
          1. Increase Aspirin to twice daily
        2. Venous thrombosis history
          1. Add Anticoagulation
      3. Refractory Course or Intolerance to Hydroxyurea (24% of patients)
        1. Younger patients
          1. Pegylated Interferon alfa-2b
            1. Adverse effects include severe skin toxicity, Asthenia
            2. Kiladjian (2008) Blood 112(8): 3065-72 [PubMed]
        2. Older patients (>70-80 years old) or advanced disease
          1. Busulfan (leukemogenicity risk)
            1. Adverse effects include cytopenia
            2. Douglas (2017) Leuk Lymphoma 58(1): 89-95 [PubMed]
        3. Symptomatic massive Splenomegaly or severe symptoms
          1. JAK2 Inhibitor (e.g. Ruxolitinib)
            1. Higher risk of Herpes Zoster infection (6% of patients)
            2. Vannucchi (2015) N Engl J Med 372(5): 426-35 [PubMed]
  12. Management: Pruritus
    1. Occurs in 68% of patients (severe in 15%)
    2. Symptomatic Therapy
      1. Aspirin
      2. Antihistamines
      3. Paroxetine
      4. Oatmeal Bath
    3. Refractory cases
      1. Interferon alfa-2b
      2. Ruxolitinib
      3. Narrow Band Ultraviolet BPhototherapy
    4. References
      1. Diehn (2001) Br J Haematol 115:619-21 [PubMed]
  13. Management: Pregnancy
    1. Polycythemia Vera is rare in pregnancy (<0.03 per 100,000)
    2. Stop Teratogenic medications (e.g. Hydroxyurea) at least 3 months before conception
      1. If Myelosuppression is needed, Interferon-alpha is the preferred cytoreductive agent in pregnancy
    3. Continue low dose Aspirin
    4. Maintain Hematocrit at Gestational age appropriate levels
    5. Avoid Iron Supplementation unless low
    6. Enoxaparin (Lovenox) for first 6 weeks postpartum to prevent Venous Thromboembolism
  14. Prognosis: General
    1. Median survival in symptomatic patients
      1. Survival without treatment: 6-18 months (up to 2 years)
        1. Death is typically due to thrombosis
      2. Survival with treatment: >8-10 years
        1. Median survival if diagnosed before age 60 years: 24 years
        2. Median survival with Aspirin and Hydroxyurea : 13.5 to 14.1 years
        3. Median survival in age over 60 years with thrombosis history: 8.3 years
    2. Malignant transformation or Myelofibrosis risk
      1. Acute Myeloid Leukemia or Myelodysplastic Syndrome risk in 15 years: 5 to 18%
      2. Myelofibrosis risk in 15 years: 6 to 14%
    3. Factors associated with poor prognosis
      1. Age over 60 years
      2. Thrombosis history
      3. Leukocytosis
      4. Abnormal karyotype
      5. High JAK2 levels
      6. Cardiovascular Risk Factors (e.g. Tobacco Abuse, Hypertension, Hyperlipidemia, Diabetes Mellitus)
  15. References
    1. Tefferi in Schrier (2015) Clinical Manifestations and Diagnosis of Polycythemia Vera, UpToDate, accessed 12/15/2015
    2. Tefferi in Schrier (2015) Prognosis and Treatment of Polycythemia Vera, UpToDate, accessed 12/15/2015
    3. Fox (2021) Am Fam Physician 103(11): 680-7 [PubMed]
    4. Griesshammer (2015) Ann Hematol 94(6):901-10 +PMID:25832853 [PubMed]
    5. Stuart (2004) Am Fam Physician 69(9):2139-46 [PubMed]
    6. Tefferi (2001) Am J Med 109:146 [PubMed]
    7. Tefferi (2003) Mayo Clin Proc 78:174-94 [PubMed]

Polycythemia Vera (C0032463)

Definition (CHV) a condition that produces excessive red blood cells
Definition (CHV) a condition that produces excessive red blood cells
Definition (CHV) a condition that produces excessive red blood cells
Definition (CHV) a condition that produces excessive red blood cells
Definition (CHV) a condition that produces excessive red blood cells
Definition (CHV) a condition that produces excessive red blood cells
Definition (CHV) a condition that produces excessive red blood cells
Definition (CHV) a condition that produces excessive red blood cells
Definition (CHV) a condition that produces excessive red blood cells
Definition (CHV) a condition that produces excessive red blood cells
Definition (CHV) a condition that produces excessive red blood cells
Definition (CHV) a condition that produces excessive red blood cells
Definition (CHV) a condition that produces excessive red blood cells
Definition (CHV) a condition that produces excessive red blood cells
Definition (MSHCZE) Krevní onemocnění charakterizované zvýšenou tvorbou červených krvinek, ale též některých bílých krvinek, granulocytů a krevních destiček v kostní dřeni a jejich zmnožením v krvi. Druh myeloproliferativního onemocnění, hladina erytropoetinu je na rozdíl od sekundární polycytemie nízká. Probíhá chronicky, kromě celkových příznaků bývají zejm. oběhové poruchy způsobené zvýšenou viskozitou krve a jejím větším množstvím a krvácivé či trombotické komplikace; může být hyperurikemie. Nápadný je vzhled nemocných s výraznou pletorou. Po řadě let někdy vyústí v jiné, závažnější krevní onemocnění charakteru leukemie nebo do fibrózy kostní dřeně. Léčí se opakovanými krevními odběry, erytrocytaferézou, některými cytostatiky či podáním radioaktivního fosforu. (cit. Velký lékařský slovník online, 2012 http://lekarske.slovniky.cz/ )
Definition (NCI_NCI-GLOSS) A disease in which there are too many red blood cells in the bone marrow and blood, causing the blood to thicken. The number of white blood cells and platelets may also increase. The extra blood cells may collect in the spleen and cause it to become enlarged. They may also cause bleeding problems and make clots form in blood vessels.
Definition (NCI) A chronic myeloproliferative neoplasm characterized by an increased red blood cell production. Excessive proliferation of the myeloid lineage is observed as well. The major symptoms are related to hypertension or to vascular abnormalities caused by the increased red cell mass. The cause is unknown. With currently available treatment, the median survival exceeds 10 years. (WHO, 2001)
Definition (MSH) A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.
Definition (CSP) myeloproliferative disorder characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume; associated frequently with splenomegaly, leukocytosis, and thrombocythemia.
Concepts Neoplastic Process (T191)
MSH D011087
ICD9 238.4
ICD10 D45, M9950/1
SnomedCT 31569001, 278190000, 134182002, 269652000, 154644004, 109992005, 128841001
English Osler Vaquez Disease, Osler-Vaquez Disease, Disease, Osler-Vaquez, Erythremia, Erythremias, PPP-Primary prolif polycythaem, Prim proliferat polycythaemia, Prim proliferat polycythemia, Erythraemia, POLYCYTHEMIA RUBRA VERA, POLYCYTHEMIA VERA, PRV, OSLER VAQUEZ DIS, [M]Polycythaemia rubra vera, [M]Polycythaemia vera, [M]Polycythemia rubra vera, [M]Polycythemia vera, polycythemia vera, polycythemia vera (diagnosis), Polycythaemia vera -RETIRED-, Primary polycythemia, Polycythemia Vera [Disease/Finding], Vera, Polycythemia Rubra, Polycythemia Rubra Veras, Polycythemia Rubra Vera, Veras, Polycythemia Rubra, erythraemia, polycythaemia vera, proliferative polycythemia, vaquez's disease, p vera, primary polycythemia, splenomegalic polycythemia, erythrocythemia, osler's disease, Polycythemia Ruba Vera, Primary Polycythemia, Erythremia (morphologic abnormality), [M]Polycythemia vera (morphologic abnormality), PV, Polycythemia rubra vera, Polycythemia vera, Osler's disease, Vaquez's disease, PPP - Primary proliferative polycythaemia, PPP - Primary proliferative polycythemia, PRV - Polycythaemia rubra vera, PRV - Polycythemia rubra vera, Polycythaemia rubra vera, Polycythaemia vera, Primary proliferative polycythaemia, Primary proliferative polycythemia, Chronic erythraemia [obs], Chronic erythremia [obs], Osler-Vaquez syndrome, Polycythaemia vera (clinical), Polycythemia vera (clinical), Polycythemia vera (disorder), Polycythemia vera (morphologic abnormality), Proliferative polycythaemia, Proliferative polycythemia, p.vera, polycythemia ruba vera, Osler-Vaquez, Vaquez-Osler, erythremia, polycythemia; rubra vera, polycythemia; vera, rubra; polycythemia rubra vera, vera; polycythemia, Polycythemia vera -RETIRED-, Polycythemia Vera, Primary polycythaemia, polycythaemia rubra vera, polycythemia rubra vera
Dutch primaire polycytemie, polycythaemia rubra vera, polycytemie vera, polycytemie rubra vera, ziekte van Vaquez, polycytemie; rubra vera, polycytemie; vera, rubra; polycythaemia rubra vera, vera; polycythaemia vera, polycythaemia vera, Erythremie, Polycythaemia vera, Vasquez-Osler-ziekte, Ziekte van Vasquez-Osler
French Polyglobulie essentielle, Maladie de Vasquez, Polyglobulie primaire, Polyglobulie primitive, Polycythémie vraie, Polyglobulie primitive essentielle, Maladie de Vaquez, Polyglobulie vraie
German Polycythaemia rubra vera, primaere Polyzythaemie, Vaquez Syndrom, Polycathaemia vera, Polycythaemia vera, Vasquez-Osler-Syndrom, Erythrämie
Italian Policitemia primitiva, Malattia di Vasquez, Malattia di Osler-Vaquez, Eritremia, Policitemia vera
Portuguese Policitemia rubra vera, Policitemia primária, Doença de Vaquez, Policitemia Rubra Vera, Policitemia vera, Doença de Osler-Vasquez, Eritremia, Policitemia Vera
Spanish Policitemia rubra vera, Policitemia primaria, Enfermedad de Vázquez, Policitemia rubra verdadera, Policitemia verdadera, Policitemia Rubra Vera, [M] policitemia vera, policitemia vera (concepto no activo), eritremia, policitemia rubra vera (anomalía morfológica), eritremia (anomalía morfológica), policitemia rubra vera, eritremia crónica, eritrocitemia, policitemia proliferativa, policitemia vera (clínica), policitemia vera (trastorno), policitemia vera, policitemia verdadera (anomalía morfológica), policitemia verdadera (clínica), policitemia verdadera (trastorno), policitemia verdadera, síndrome de Osler - Vasquez, Policitemia vera, Enfermedad de Osler-Vaquez, Eritremia, Policitemia Vera
Japanese 原発性多血症, 原発性赤血球増加症, ゲンパツセイタケツショウ, ゲンパツセイセッケッキュウゾウカショウ, バケービョウ, シンセイタケツショウ, シンセイセッケッキュウゾウカショウ, オスラー・ワーケ病, オスラー・バケー病, Osler-Vaquez病, 多血症-真性, 真性多血症, 真性赤血球増加症, 真正多血症, 真正赤血球増加症, 赤血球増加症-真性, 赤血病-慢性, 赤血病, オスラー-ワーケ病, バケー-オスラー病, バケー病, 多血症-真正
Swedish Polycytemia vera
Czech polycythemia vera, Vasquezova choroba, Polycytemia vera, Primární polycytemie, Polycytemia rubra vera, polycythaemia vera, Oslerova-Vaquezova nemoc, polycythaemia rubra vera, pravá polycytemie
Finnish Itsenäinen polysytemia
Russian ERITREMIIA, OSLERA-VAKEZA BOLEZN', POLITSITEMIIA ISTINNAIA, ОСЛЕРА-ВАКЕЗА БОЛЕЗНЬ, ПОЛИЦИТЕМИЯ ИСТИННАЯ, ЭРИТРЕМИЯ
Korean 진성 적혈구 증가증
Croatian POLICITEMIJA RUBRA VERA
Polish Choroba Oslera-Vaqueza, Czerwienica prawdziwa
Hungarian Polycythaemia rubra vera, Primaer polycythaemia, Vaquez-betegség, Polycytemia rubra vera, Elsődleges polycythaemia, Polycythaemia vera
Norwegian Polycythaemia rubra vera, Polycythaemia vera
Sources
Derived from the NIH UMLS (Unified Medical Language System)


You are currently viewing the original 'fpnotebook.com\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree